Respiratory syncytial virus vaccine - Pierre Fabre

Drug Profile

Respiratory syncytial virus vaccine - Pierre Fabre

Alternative Names: BBG2Na; F50077; J002X; L0077

Latest Information Update: 19 Oct 2005

Price : $50

At a glance

  • Originator Pierre Fabre
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 19 Oct 2005 No development reported - Phase-II for Respiratory syncytial virus infections in France (IM)
  • 26 Jun 2001 A phase II trial has been added to the adverse events and Viral Infections therapeutic trials sections
  • 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top